Item type |
itemtype_ver1(1) |
公開日 |
2022-10-17 |
タイトル |
|
|
タイトル |
Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01) |
|
言語 |
en |
著者 |
Yamaguchi, Junpei
Yokoyama, Yukihiro
Fujii, Tsutomu
Yamada, Suguru
Takami, Hideki
Kawashima, Hiroki
Ohno, Eizaburo
Ishikawa, Takuya
Maeda, Osamu
Ogawa, Hiroshi
Kodera, Yasuhiro
Nagino, Masato
Ebata, Tomoki
|
アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
権利 |
|
|
言語 |
en |
|
権利情報 |
"This is a non-final version of an article published in final form in (Yamaguchi, Junpei; Yokoyama, Yukihiro; Fujii, Tsutomu; Yamada, Suguru; Takami, Hideki; Kawashima, Hiroki; Ohno, Eizaburo; Ishikawa, Takuya; Maeda, Osamu; Ogawa, Hiroshi; Kodera, Yasuhiro; Nagino, Masato; Ebata, Tomoki. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Annals of Surgery: June 2022 - Volume 275 - Issue 6 - p 1043-1049 doi: 10.1097/SLA.0000000000005430)." |
内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Objective: Given the frequent adverse events with multidrug chemotherapy, not only the survival benefit but also the feasibility of using neoadjuvant chemotherapy to treat pancreatic cancer need to be clarified. Summary of Background Data: Although the development of multidrug chemotherapy regimens has improved the survival outcomes of patients with unresectable pancreatic cancer, the benefits of these treatments in the neo-adjuvant setting remain controversial. Methods: Patients with borderline-resectable pancreatic cancer were enrolled and randomly assigned to receive neoadjuvant chemotherapy with either FOLFIRINOX or gemcitabine with nab-paclitaxel (GEM/nab-PTX). After the completion of chemotherapy, patients underwent surgical resection when feasible. This study (NUPAT-01) was a randomized phase II trial, and the primary endpoint was the R0 resection rate. Results: Fifty-one patients were enrolled in this study [FOLFIRINOX (n = 26) and GEM/nab-PTX (n = 25)]. A total of 84.3% (n = 43/51) of the patients eventually underwent surgery, and R0 resection was achieved in 67.4% (n = 33/ 51) of the patients. Adverse events (grade >3) due to neoadjuvant treatment were observed in 45.1% of the patients (n = 23/51), and major surgical complications occurred in 30.0% (n = 13/43), with no mortality noted. The intention-to-treat analysis showed that the 3-year overall survival rate was 54.7%, with a median survival time of 39.4 months, and a significant difference in overall survival was not observed between the FOLFIRINOX and GEM/nab-PTX groups. Conclusions: These results indicate that neoadjuvant chemotherapy with FOLFIRINOX or GEM/nab-PTX is feasible and well tolerated, achieving an R0 resection rate of 67.4%. The survival of patients was even found to be favorable in the intention-to-treat analysis. |
|
言語 |
en |
出版者 |
|
|
出版者 |
Wolters Kluwer Health |
|
言語 |
en |
言語 |
|
|
言語 |
eng |
資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1097/SLA.0000000000005430 |
収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0003-4932 |
書誌情報 |
en : Annals of Surgery
巻 275,
号 6,
p. 1043-1049,
発行日 2022-06
|
ファイル公開日 |
|
|
日付 |
2023-06-01 |
|
日付タイプ |
Available |